Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-10-12
1998-12-01
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 21, 514912, 530399, 530402, 530409, 530410, 530849, 424 7804, 424422, A61K 3800, C07K 100, A61F 1300
Patent
active
058438939
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to uses of a conjugate comprising a cytotoxic agent and a polypeptide reactive with a fibroblast growth factor (FGF) receptor.
BACKGROUND OF THE INVENTION
The FGF family currently consists of seven members. The most widely studied molecules to date, acidic and basic FGF (aFGF and bFGF), are two structurally related polypeptides of molecular weight 15000-18000 kD. They were isolated originally from bovine brain, pituitary and retinal tissues but are also present in many other tissues. Basic FGF is a mitogenic factor for most cells of mesodermal and ectodermal origin via binding to specific cell surface receptors. Indeed, high and low affinity binding sites for bFGF have been identified in baby hamster kidney (BHK) cells and many other cell types including bovine lens epithelial cells (BEL cells). Basic FGF also binds to basement membranes in a dose dependent manner probably on the polysaccharide part of the heparan sulfate proteoglycans.
Recent studies have established the feasibility of conferring cytotoxic activities to bFGF by chemically conjugating potential toxins to the growth factor. As an example, saporin is a ribosome inactivating protein isolated from Saponaria officinalis which can be chemically conjugated to bFGF. The resulting bFGF-saporin conjugate (bFGF-SAP) is a specific cytotoxin for cells expressing the bFGF receptor (Lappi et al., Biochem. Biophys. Res. Commun. 160:2, 917-923, 1989; Lappi et al, J. Cell. Physiol. 147, 17-26, 1991). Because the coupling between saporin and bFGF does not affect bFGF affinity for heparin or its high affinity receptor, the conjugate has all the characteristics of the mitogen. WO 90/125597 discloses conjugates comprising a cytotoxic agent and a polypeptide reactive with a FGF receptor, for example bFGF-SAP, for use in treating FGF-mediated pathophysiological conditions such as tumours, atherosclerosis, rheumatoid arthritis and proliferative retinopathy.
The present invention, however, is concerned with the treatment of another pathological condition. This condition is a side-effect of cataract surgery, in particular cataract surgery performed by a technique which leaves the posterior part of the lens capsule in place. The purpose of leaving in place the posterior part of the lens capsule is to maintain the vitreous fluid at its place in the eye and, most of the time, to anchor the lens implant.
In many instances, the lens cells which are left at the periphery migrate and divide. They then occupy the centre of the lens capsule and impair vision. This can occur in about 30% of cases within several months in young patients or within a year in old patients. New surgery or laser treatment is needed to break the membrane that forms, which is costly and not harmless.
We have found that a bFGF-SAP conjugate is bound tightly to a lens capsule. The presence of the conjugate prevents the migration and proliferation of epithelial lens cells. Other eye tissue, such as the corneal endothelium which controls corneal transparency, is not damaged. These findings have general applicability.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides use of a conjugate comprising a cytotoxic agent and a polypeptide reactive with a FGF receptor in the preparation of a medicament for use in inhibiting the proliferation of epithelial lens cells. In this way, the growth of residual lens epithelial cells, which are known to migrate and proliferate on the posterior lens capsule after extracapsular cataract surgery, may be interrupted to prevent secondary opacification of the capsule.
DETAILED DESCRIPTION OF THE INVENTION
Suitable conjugates are described in WO 90/12597. The polypeptide reactive with a FGF receptor is typically a FGF such as aFGF, bFGF or other proteins exhibiting bFGF mitogenic activity mediated through binding to a FGF receptor. A test for such activity is the ability to stimulate proliferation of cultured bovine aortic endothelial cells (Gospodarowicz et al, J. Biol. Chem. 257, 12266-12278, 1982; Gospodarowic
REFERENCES:
patent: 4871350 (1989-10-01), Lam et al.
patent: 5055291 (1991-10-01), Lam et al.
patent: 5191067 (1993-03-01), Lappi et al.
patent: 5308622 (1994-05-01), Casscells et al.
Abraham, et al., "Human basic fibroblast growth factor: nucleotide sequence and genomic organization," The EMBO Journal 5(10):2523-2527 (1986).
Arruti and Courtois, "Morphological Changes and Growth Stimulation of Bovine Epithelial Lens Cells by a Retinal Extract In Vitro," Exp Cell Res 117:283-292 (1978).
Azuma and Shearer, "Induction of Elongation in Cultured Rat Lens Epithelial Cells by FGF and Inhibition by Selenite," Investigative Ophthalmology & Visual Science, 33(8):2528-2531 (1992).
Baird, et al., "Angiogenic Factor in Human Ocular Fluid", The Lancet p. 563 (1985).
Baudouin et al., "Acidic Fibroblast Growth Factor Distribution in Normal Human Eye and Possible Implications in Ocular Pathogenesis," Ophthalmic Res 22:73-81 (1990).
Beattie, et al., "Selective elimination of fibroblasts from pancreatic islet monolayers by basic fibroblast growth factor-saporin mitotoxin," Chemical Abstracts 113(19), Abstract No. 166052v.
Benatti, et al., "Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from Saponaria officinalis," Eur J Biochem 183:465-470 (1989).
Bikfalvi, et al., "Binding, Internalization, and Degradation of Basic Fibroblast Growth Factor in Human Microvascular Endothelial Cells," Exp Cell Res 181:75-84 (1989).
Blanquet, et al., "Identification and Isolation From Bovine Epithelial Lens Cells of Two Basic Fibroblast Growth Factor Receptors That Possess bFGF-Enhanced Phosphorylation Activities," Biochem and Biophys Res Comm 160(3):1124-1131 (1989).
Bohlen, et al., "Isolation and partial molecular characterization of pituitary fibroblast growth factor," Proc. Natl. Acad. Sci. USA 81:5364-5368 (1984).
Chaudhary, et al., "Activity of a recombinant fusion protein between transforming growth factor type .alpha. and Pseudomonas toxin," Proc. Natl. Acad. Sci. USA 84:4538-4542 (1987).
Courty, et al., "Evidence for FGF-Like Growth Factor in Adult Bovine Retina: Analogies With EDGF I," Biochem and Biophys Res Comm 136(1):102-108 (1986).
Courty, et al., "Bovine retina contains three growth factor activities with different affinity to heparin: eye derived growth factor I, II, III," Biochimie 67:265-269 (1985).
Dabin and Courtois, "In Vitro Kinetics of Basic Fibroblast Growth Factor Diffusion Across a Reconstituted Corneal Endothelium," J Cell Physiol 147:396-402 (1991).
David, et al., "Biphasic Effect of the Mitoxin bFGF-Saporin on Bovine Lens Epithelial Cell Growth: Effect of Cell Density and Extracellular Matrix," J Cell Physiol 153:483-490 (1992).
Gospodarowicz, et al., "Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: Identify with pituitary fibroblast growth factor," Proc. Natl. Acad. Sci. USA 81:6963-6967 (1984).
Gospodarowicz, et al., "Purification in High Yield of Brain Fibroblast Growth Factor by Preparative Isoelectric Focusing at pH 9.6," J Biol Chem 257(20):12266-12276 (1982).
Gospodarowicz, et al., "Clonal growth of bovine vascular endothelial cells: Fibroblast growth factor as a survival agent," Proc. Natl. Acad. Sci. USA 73(11):4120-4124 (1976).
Goureau, et al., "Differential regulation of inducible nitric oxide synthase by fibroblast growth factors and transforming growth factor .beta. in bovine retinal pigmented epithelial cells: Inverse correlation with cellular proliferation," Proc. Natl. Acad. Sci. USA 90 (1993).
Hughes, et al., "Lens Glycoproteins: Biosynthesis in Cultured Epithelial Cells of Bovine Lens," Eur J Biochem 52:143-155 (1975).
Jeanny, et al., "Specific Fixation of Bovine Brain and Retinal Acidic and Basic Fibroblast Growth Factors to Mouse Embryonic Eye Basement Membranes," Exp Cell Res 171:63-75 (1987).
Lappi, et al., "Characterization of a Saponaria Officinalis Seed Ribosome-Inactivating Protein: Immunoreactivity and Sequence Homologies", Biochem and Biophys Res Comm 12
Mohamed Abdel A.
Pharmacia S.p.A.
Tsang Cecilia J.
LandOfFree
Method for inhibiting the proliferation of epithelial lens cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting the proliferation of epithelial lens cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting the proliferation of epithelial lens cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395641